KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash from Operations (2016 - 2025)

BeOne Medicines (ONC) has disclosed Cash from Operations for 11 consecutive years, with 417347000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 455.28% to 417347000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1127580000.0, a 901.8% increase, with the full-year FY2025 number at 1127580000.0, up 901.8% from a year prior.
  • Cash from Operations was 417347000.0 for Q4 2025 at BeOne Medicines, up from 402553000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 417347000.0 in Q4 2025 to a low of 563777000.0 in Q1 2023.
  • A 5-year average of 116545750.0 and a median of 158613000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 350.36% in 2022, then soared 455.28% in 2025.
  • BeOne Medicines' Cash from Operations stood at 127092000.0 in 2021, then tumbled by 350.36% to 318191000.0 in 2022, then soared by 30.34% to 221638000.0 in 2023, then soared by 133.91% to 75160000.0 in 2024, then skyrocketed by 455.28% to 417347000.0 in 2025.
  • Per Business Quant, the three most recent readings for ONC's Cash from Operations are 417347000.0 (Q4 2025), 402553000.0 (Q3 2025), and 263598000.0 (Q2 2025).